Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2018-02-08 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Notification regarding release of restricted securities 2 pages 156.3KB
Capital/Financing Update Classification · 95% confidence The document is a notice regarding the release of securities from mandatory escrow and a correction to an Appendix 3B filing. It references ASX Listing Rule 3.10A and details about shares subject to escrow and quotation. The document is short (2670 characters) and primarily provides an update on share escrow status and a correction to a previously lodged Appendix 3B. It does not contain financial statements, detailed financial analysis, or management discussion. It is an announcement related to capital structure and share status, specifically about share release from escrow and correction of share counts. This fits best under Capital/Financing Update (CAP) as it concerns share capital and escrow release information, which is a financing activity update.
2018-02-08 English
Appendix 4C - December 2017 quarter 6 pages 571.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C – December 2017 quarter' and is described as a quarterly report for entities subject to Listing Rule 4.7B of the ASX. It contains detailed financial data including consolidated statements of cash flows for the quarter and year to date, cash reserves, cash inflows and outflows, financing activities, and estimated cash outflows for the next quarter. The document also includes compliance statements and notes referencing accounting standards. The length of the document (over 11,000 characters) and the presence of substantive financial data confirm it is a financial report rather than a brief announcement or certification. The quarterly nature and detailed financial statements align with the definition of an Interim / Quarterly Report (IR). Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q4 2017
2018-01-29 English
App 3B - shares released from ASX mandatory escrow 13 pages 140.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities, terms, issue price, purpose, and compliance with ASX rules. It includes sections on placement capacity calculations under ASX Listing Rules 7.1 and 7.1A, escrow restrictions, and quotation agreements. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new issue of shares and related securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not a brief notice or report publication announcement.
2018-01-14 English
Summary of voluntary escrow arrangements 1 page 157
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Telix Pharmaceuticals Limited regarding voluntary escrow arrangements on shares following their listing on the ASX. It references an Appendix 3B lodged on the same day and provides details about the number and timing of shares under escrow. The document does not contain financial statements, detailed financial analysis, or management discussion. It is primarily an update on share escrow status, which relates to capital structure and share trading restrictions. The document length is 2323 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as escrow arrangements on shares.
2018-01-14 English
Telix establishes Japanese subsidiary 2 pages 327.2KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the establishment of a Japanese subsidiary and the appointment of key executives for Telix Pharmaceuticals Limited. It focuses on corporate organizational changes and leadership appointments rather than financial results, regulatory filings, or shareholder information. There is no indication of financial data, report publication, or voting results. The content aligns with announcements about changes in the company's board or senior management. Therefore, the document fits best under the category 'Board/Management Information' (MANG). The document length is 4402 characters, which is consistent with a typical announcement rather than a full report.
2018-01-14 English
Notification regarding release of restricted securities 1
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the release of securities from escrow, referencing ASX Listing Rule 3.10A. It does not contain financial statements, detailed financial data, or management discussion. The length is only 1409 characters, which is quite brief and typical of a regulatory announcement. It is not an annual or interim report, nor an earnings release or management report. It is not a proxy or voting result announcement. The content fits best with a Regulatory Filing (RNS) as it is a compliance-related disclosure about securities escrow release under ASX rules.
2017-12-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.